Go Pro
→ Elon Is Quietly Doubling Down on This Bizarre Asset (From Brownstone Research) (Ad)tc pixel Free TNDM Stock Alerts

Tandem Diabetes Care (TNDM) Competitors

Tandem Diabetes Care logo
$16.25 +0.84 (+5.45%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$16.29 +0.04 (+0.23%)
As of 09:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TNDM vs. IRTC, WRBY, ESTA, AXGN, and TMDX

Should you buy Tandem Diabetes Care stock or one of its competitors? MarketBeat compares Tandem Diabetes Care with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tandem Diabetes Care include iRhythm Technologies (IRTC), Warby Parker (WRBY), Establishment Labs (ESTA), AxoGen (AXGN), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.

How does Tandem Diabetes Care compare to iRhythm Technologies?

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Tandem Diabetes Care has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

In the previous week, Tandem Diabetes Care had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 4 mentions for Tandem Diabetes Care and 3 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 1.24 beat iRhythm Technologies' score of 0.62 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iRhythm Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

iRhythm Technologies has a net margin of -3.53% compared to Tandem Diabetes Care's net margin of -9.20%. iRhythm Technologies' return on equity of -10.26% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-9.20% -53.88% -7.88%
iRhythm Technologies -3.53%-10.26%-1.39%

Tandem Diabetes Care currently has a consensus target price of $29.13, indicating a potential upside of 79.23%. iRhythm Technologies has a consensus target price of $187.38, indicating a potential upside of 57.89%. Given Tandem Diabetes Care's higher possible upside, research analysts plainly believe Tandem Diabetes Care is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.94

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.10-$204.71M-$1.40N/A
iRhythm Technologies$747.14M5.22-$44.55M-$0.86N/A

Summary

iRhythm Technologies beats Tandem Diabetes Care on 9 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Warby Parker?

Warby Parker (NYSE:WRBY) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

93.2% of Warby Parker shares are owned by institutional investors. 16.8% of Warby Parker shares are owned by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Warby Parker has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Warby Parker currently has a consensus target price of $29.82, indicating a potential upside of 8.55%. Tandem Diabetes Care has a consensus target price of $29.13, indicating a potential upside of 79.23%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
0 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.67
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

In the previous week, Warby Parker and Warby Parker both had 4 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.24 beat Warby Parker's score of 0.41 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tandem Diabetes Care
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Warby Parker has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$871.91M3.37$1.64M$0.021,373.45
Tandem Diabetes Care$1.01B1.10-$204.71M-$1.40N/A

Warby Parker has a net margin of 0.15% compared to Tandem Diabetes Care's net margin of -9.20%. Warby Parker's return on equity of 2.30% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker0.15% 2.30% 1.18%
Tandem Diabetes Care -9.20%-53.88%-7.88%

Summary

Warby Parker beats Tandem Diabetes Care on 12 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Establishment Labs currently has a consensus price target of $89.71, suggesting a potential upside of 2.06%. Tandem Diabetes Care has a consensus price target of $29.13, suggesting a potential upside of 79.23%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Establishment Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Establishment Labs has higher earnings, but lower revenue than Tandem Diabetes Care. Establishment Labs is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$211.08M12.26-$51.06M-$1.49N/A
Tandem Diabetes Care$1.01B1.10-$204.71M-$1.40N/A

In the previous week, Tandem Diabetes Care had 2 more articles in the media than Establishment Labs. MarketBeat recorded 4 mentions for Tandem Diabetes Care and 2 mentions for Establishment Labs. Tandem Diabetes Care's average media sentiment score of 1.24 beat Establishment Labs' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Establishment Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tandem Diabetes Care
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tandem Diabetes Care has a net margin of -9.20% compared to Establishment Labs' net margin of -19.05%. Tandem Diabetes Care's return on equity of -53.88% beat Establishment Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Establishment Labs-19.05% -218.77% -12.31%
Tandem Diabetes Care -9.20%-53.88%-7.88%

Summary

Tandem Diabetes Care beats Establishment Labs on 12 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AxoGen and AxoGen both had 4 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.24 beat AxoGen's score of 1.08 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AxoGen
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tandem Diabetes Care
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tandem Diabetes Care has a net margin of -9.20% compared to AxoGen's net margin of -13.21%. AxoGen's return on equity of -9.63% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
AxoGen-13.21% -9.63% -6.26%
Tandem Diabetes Care -9.20%-53.88%-7.88%

AxoGen has higher earnings, but lower revenue than Tandem Diabetes Care. AxoGen is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$225.21M9.32-$15.70M-$0.64N/A
Tandem Diabetes Care$1.01B1.10-$204.71M-$1.40N/A

AxoGen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 17.75%. Tandem Diabetes Care has a consensus price target of $29.13, suggesting a potential upside of 79.23%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than AxoGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Summary

AxoGen beats Tandem Diabetes Care on 8 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to TransMedics Group?

Tandem Diabetes Care (NASDAQ:TNDM) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

99.7% of TransMedics Group shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TransMedics Group had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 6 mentions for TransMedics Group and 4 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.24 beat TransMedics Group's score of 0.65 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TransMedics Group
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tandem Diabetes Care has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Tandem Diabetes Care currently has a consensus target price of $29.13, indicating a potential upside of 79.23%. TransMedics Group has a consensus target price of $134.50, indicating a potential upside of 77.58%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45
TransMedics Group
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

TransMedics Group has a net margin of 27.04% compared to Tandem Diabetes Care's net margin of -9.20%. TransMedics Group's return on equity of 22.38% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-9.20% -53.88% -7.88%
TransMedics Group 27.04%22.38%8.46%

TransMedics Group has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.01B1.10-$204.71M-$1.40N/A
TransMedics Group$605.49M4.32$190.29M$4.4017.21

Summary

TransMedics Group beats Tandem Diabetes Care on 11 of the 17 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNDM vs. The Competition

Export
MetricTandem Diabetes CareMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.06B$7.63B$7.05B$12.61B
Dividend YieldN/A1.32%2.68%8.00%
P/E Ratio-11.6150.2827.1024.26
Price / Sales1.1076.45588.85117.88
Price / CashN/A26.8529.2249.36
Price / Book7.107.3210.856.29
Net Income-$204.71M$162.30M$3.58B$330.66M
7 Day Performance5.31%-0.99%-2.12%-1.35%
1 Month Performance-2.11%0.19%3.27%-0.64%
1 Year Performance3.17%4.08%26.33%19.08%

Tandem Diabetes Care Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNDM
Tandem Diabetes Care
2.6523 of 5 stars		$16.25
+5.5%		$29.13
+79.2%		+4.2%$1.06B$1.01BN/A2,500
IRTC
iRhythm Technologies
3.7978 of 5 stars		$126.03
-0.4%		$187.38
+48.7%		-12.7%$4.16B$747.14MN/A2,400
WRBY
Warby Parker
2.8789 of 5 stars		$29.28
+0.1%		$29.82
+1.9%		+23.7%$3.13B$871.91M1,464.484,036
ESTA
Establishment Labs
1.2964 of 5 stars		$91.56
+2.6%		$87.14
-4.8%		+95.8%$2.63B$211.08MN/A1,004
AXGN
AxoGen
2.9801 of 5 stars		$45.97
+0.2%		$46.50
+1.2%		+232.1%$2.44B$225.21MN/A450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Under $1 while the market panics
The new deadline for crypto’s best bill, the Clarity Act, is August 7th. That's the Senate's final session day...
Crypto 101 Media | Sponsoredtc pixel
They told you not to miss this one
The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...
Thor Metals | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
They proved it worked in '76. Then buried it.
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel